Company Overview
| Stock Name | Charmacy Phar |
|---|---|
| Stock Code | 02289 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是華南地區領先的醫藥分銷商之一,主要於中國分銷藥品,向醫藥分銷商客戶、零售藥店及醫院、診所、衛生站及其他分銷醫藥產品,亦向供應商提供營銷策略諮詢服務及有關信息服務。 |
| Listing Date | 2015-12-14 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | To be extracted |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 廣東省汕頭市龍湖區嵩山北路235號 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東28號金鐘滙中心18樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | chmyy.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | To be extracted |
|---|---|
| Offer Price | HK$ 8.60 / shares |
| Offer Price Range | To be extracted |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | RMB 1.0 / shares |
| Offer Period | 2015-12-02 to 2015-12-07 |
| Global Offering Shares | 28,000,000 shares |
| HK Public Offer Shares (Initial) | 2,800,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 25,200,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 108,000,000 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 10.5% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 240,800,000 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 599.5M |
| Est. Threshold | HK$ 9.71B |
| Analysis Result | HK market cap below threshold, need +1520% |
Valuation & Financials
| Market Cap (at Offer Price) | To be extracted |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | Not disclosed |
| Profit/Loss Status | 盈利約人民幣36.4百萬元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2012 | 2013 | 2014 | 2015-06 |
|---|---|---|---|---|
| Revenue | 2,016,943 | 2,401,231 | 3,014,059 | 1,635,397 |
| Cost of sales | -1,929,662 | -2,297,253 | -2,877,618 | -1,551,784 |
| Gross profit | 87,281 | 103,978 | 136,441 | 83,613 |
| Other income and gains, net | 4,405 | 4,995 | 5,245 | 2,818 |
| Selling and distribution expenses | -22,385 | -25,137 | -35,757 | -18,504 |
| Administrative expenses | -29,076 | -33,972 | -37,162 | -22,674 |
| Operating profit | 40,225 | 49,864 | 68,767 | 45,253 |
| Net finance costs | -19,660 | -20,550 | -22,832 | -11,538 |
| Profit before tax | 20,565 | 29,314 | 45,935 | 33,715 |
| Income tax expense | -6,454 | -7,095 | -9,490 | -8,481 |
| Profit for the year | 14,111 | 22,219 | 36,445 | 25,234 |
| Profit attributable to owners | 14,111 | 22,219 | 36,445 | 25,234 |
Balance Sheet
| Item | 2012 | 2013 | 2014 | 2015-06 |
|---|---|---|---|---|
| Cash and cash equivalents | 12,346 | 16,761 | 22,296 | 24,702 |
| Trade and bills receivables | 543,298 | 721,210 | 864,395 | 979,627 |
| Inventories | 210,856 | 256,746 | 244,935 | 242,087 |
| Total current assets | 950,973 | 1,239,999 | 1,336,972 | 1,521,389 |
| Total assets | 1,163,059 | 1,444,602 | 1,533,936 | 1,712,816 |
| Total current liabilities | 976,158 | 1,235,482 | 1,288,371 | 1,472,017 |
| Total liabilities | 976,158 | 1,235,482 | 1,288,371 | 1,472,017 |
| Total equity | 186,901 | 209,120 | 245,565 | 240,799 |
| Equity attributable to owners | 186,901 | 209,120 | 245,565 | 240,799 |
| Interest-bearing borrowings | 258,494 | 299,560 | 301,350 | 278,750 |
Cash Flow Statement
| Item | 2012 | 2013 | 2014 | 2015-06 |
|---|---|---|---|---|
| Net cash from operating activities | 61,700 | 45,104 | -14,826 | 134,379 |
| Net cash from investing activities | -104,218 | -61,705 | 40,903 | -67,835 |
| Net cash from financing activities | 41,854 | 21,016 | -20,542 | -64,138 |
| Net increase in cash | -664 | 4,415 | 5,535 | 2,406 |
| Depreciation of PP&E | 7,063 | 9,967 | 9,725 | 4,411 |
| Amortisation of intangible assets | 2,215 | 2,215 | 2,215 | 1,108 |
| Purchase of PP&E | -41,833 | -5,104 | -4,447 | -497 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 8.0 |
|---|---|
| First Day Open | HK$ 7.7 |
| First Day Change | -6.98% |
| First Day Volume | 8018500.0 |
| First Day Turnover | 64439800.0 |
| Use of Proceeds | 1、約64.8百萬港元(約35%)將用于增強、擴展及整合我們現存的分銷網絡及能力;
2、約18.5百萬港元(約10%)將用于改良及推廣我們的B2B電子商務平臺;
3、約55.6百萬港元(約30%)將用于償還銀行借款;
4、約27.8百萬港元(約15%)將用于收購華南地區的醫藥分銷業務;
5、約18.5百萬港元(約10%)用于營運資金及一般企業用途。 |
Underwriting Syndicate
Sole Sponsor (1)
国泰君安融资有限公司 CE AGS488
Overall Coordinators (1)
国泰君安证券(香港)有限公司 CE ABY236
Joint Bookrunners (1)
国泰君安证券(香港)有限公司 CE ABY236
Joint Lead Managers (3)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | 广药白云山香港有限公司 | 67,995,900 HKD | — | 7.30% | — | 6 months | 2016-06-14 |
| 2 | 香雪集团(香港)有限公司 | 29,996,800 HKD | — | 3.20% | — | 6 months | 2016-06-14 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 姚創龍 | — |
| Company Secretary | 林志雄、吳詠珊 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 姚先生(董事會主席)實益持有70,000,000股內資股(87.5%),配偶權益1,000,000股(1.25%);游澤燕女士(配偶)持有配偶權益及受控法團權益;姚女士(姚先生之母)實益持有6,500,000股內資股(8.125%)。上市後姚先生及游澤燕女士各約65.74%,姚女士約6.01%。 |
|---|




